Introduction: Ambulatory individuals with spinal muscular atrophy (SMA) experience muscle weakness, gait impairments, and fatigue that affect their walking ability.
Results: Fourteen children performed the 6MWT. Median (25th, 75th percentile) distance walked increased over time by 98.0 (62.0, 135.0) meters at day 1050, whereas median fatigue changed by −3.8% (−19.7%, 1.4%).
Discussion: These results support previous studies demonstrating clinically meaningful effects of nusinersen on motor function in children and adolescents with lateronset SMA. Spinal muscular atrophy (SMA) is a chronic autosomal recessive neuromuscular disorder characterized by progressive muscle atrophy and weakness caused by biallelic disruption of the survival motor neuron 1 (SMN1) gene. 1, 2 SMA manifests in different phenotypes defined by age of symptom onset and maximum motor milestone achievement. 2, 3 SMA type II and III are milder forms than type I, with symptom onset at age 7-18 months and >18 months, respectively. 4 Individuals with SMA type III attain the ability to walk unaided at some point; however, muscle weakness causes gait impairment and reduced endurance. 5 Over time, patients may lose the ability to walk independently. 2 Tools assessing walking ability and fatigue are clinically relevant in individuals with milder forms of SMA. 5 All children who received their first nusinersen dose in the CS2 study, were ambulatory during CS2 or CS12, and performed the 6MWT were included in these analyses.
is a valid and clinically meaningful measure of ambulatory function and has demonstrated sensitivity to fatigue-related changes in individuals with SMA. [6] [7] [8] [9] Fatigue measured during the 6MWT may represent underlying disease-specific mechanisms, 10 and improvements may represent treatment benefit. Neuromuscular junction (NMJ) development and maturation abnormalities, including immaturity, denervation, and neurofilament accumulation, as well as endocytosis and axonal transport abnormalities, have been identified in animal models and in individuals with SMA. [11] [12] [13] [14] Data suggesting a relationship between NMJ dysfunction and fatigability have been reported. 11, 15 Nusinersen is the first drug approved for the treatment of SMA, 16, 17 and has demonstrated significant and clinically meaningful efficacy by increasing event-free survival, motor function, and achievement of motor milestones in infantile-onset SMA, 18 and improving/maintaining motor function in later-onset SMA. 19, 20 Nusinersen has resulted in clinically meaningful improvements in walking ability (defined as ≥30-meter increase from baseline in 6MWT distance) in children/adolescents with later-onset SMA 6, 20, 21 ; however, the effects of nusinersen treatment on fatigability are unknown. In this post hoc analysis we further examined 6MWT performance and the relationship between distance walked and fatigue in the subgroup of nusinersen-treated children and adolescents with SMA who were ambulatory during the CS2 dose-escalation or CS12 extension studies and completed the 6MWT. Given that participants of ambulatory age were followed for~3 years, these studies provide the opportunity to evaluate longer-term nusinersen treatment effects on 6MWT fatigability in individuals with SMA. All children who received their first nusinersen dose in the CS2 study, were ambulatory during CS2 or CS12, and performed the 6MWT were included in these analyses. b This motor milestone history item was reported as "no" in 1 case, but the participant was able to stand independently according to the Hammersmith Functional Motor Scale Expanded item "Stand unsupported." c One participant with SMA type II gained the ability to walk independently during the course of the study.
| METHODS
d Two participants were able to walk a short distance or <25 meters, and did not have 6MWT performed at baseline; the 6MWT total distance was imputed as 0 meters at baseline.
approach was utilized in which study days were derived from the first day of CS2 dosing for all CS2 and CS12 study visits.
Changes in 6MWT distance and fatigue over 253 and 1050 days were evaluated. The 6MWT measures the distance a person can walk quickly in 6 minutes; details of test administration have been described elsewhere. 7 Briefly, participants were instructed to walk as quickly as possible along a 25-meter linear course, turn around a cone, return in the opposite direction, and repeat the loop as many times as possible for 6 minutes. Tests were administered by trained physical therapists;
distance walked at each minute was recorded. Fatigue was calculated by subtracting the distance walked in the sixth minute from the distance walked in the first minute. Measurements are expressed as percentages, where a positive value represents fatigue. Correlations between 6MWT distance and fatigue at baseline and day 1050 were evaluated using Pearson correlation analysis. Subgroup analyses compared results in participants aged ≤11 years with those aged >11 years;
these age groups are similar to those reported previously. 5, 22 3 | RESULTS Fourteen children were included in the analyses. All participants had SMA type III, except for 1 participant with SMA type II who achieved the ability to walk independently and performed the 6MWT during the CS12 study (Table 1) . Baseline 6MWT distances and fatigue are listed in Table 2 . At baseline, participants aged ≤11 years walked farther and had less 6MWT fatigue than those aged >11 years ( Table 2) 
| DISCUSSION
Ambulatory children and adolescents treated with nusinersen in the CS2 multiple-dose and CS12 extension studies demonstrated improvements in ambulatory function (6MWT), with clinically meaningful increases in walking distance and modest decreases or stabilization in fatigue. Although there is no precedent for improvements like these in individuals with SMA, changes of ≥30 meters in 6MWT distance are considered clinically meaningful and to impact everyday activities in other pediatric neuromuscular disorders. 6, 21 Older children and adolescents with SMA are more at risk for declining ambulatory function. 5 A longitudinal natural history study of ambulatory patients with SMA type III showed that 6MWT trajectories were age-dependent. 5 The day of the first study visit attended in the CS12 study depended upon the time between the end of the CS2 study and first dose in the CS12 study and the windowing of study visits described as follows. Median (range) time from the end of the CS2 study to first dose in the CS12 study was 118.0 (19-233) days. † Study days were derived from the first day of CS2 dosing for all CS2 and CS12 study visits and were assigned visit days as follows: study visits that took place >50 and ≤131 days from the first dose in the CS2 study were labeled day 92, visits >131 and ≤211 days from the first dose in CS2 were labeled day 169, those >211 and ≤302 days were labeled day 253, those >302 and ≤400 days were labeled day 350, and study visits >X − 50 to ≤X + 50 were labeled day X (starting at day 450 and increasing by 100 until day 1050), times between visit days were not equal, but were similar. 6MWT, 6-minute walk test improvement or stabilization in 6MWT distance is unexpected in these older participants based on SMA natural history. 5 NMJ dysfunction has been identified in SMA mouse models and patients. 11, 14, 15 In individuals with SMA, fatigue on the 6MWT was associated with a decrement on low-rate repetitive nerve stimulation, possibly due to developmental NMJ abnormalities or NMJ function alterations. 11, 15 Although the mechanism remains unknown, 6MWT
fatigue implicates dysfunction at the NMJ in SMA, and has not been demonstrated by individuals with other neuromuscular disorders who exhibit weakness. 10, 15 The observed decrease or stabilization of 6MWT fatigue may represent a nusinersen treatment effect. Further understanding of the underlying mechanisms of fatigue may help explain modest treatment responses. Laboratory evidence suggests that muscle mitochondria may be vulnerable to SMN deficiency. 24, 25 Fatigue may also be the clinical consequence of these laboratory intervals. 16, 27 The time period between completion of the CS2 study and the beginning of treatment in the CS12 study was longer for children receiving lower nusinersen doses in the CS2 study; therefore, children in the CS2 9-and 12-mg dosing cohorts may have reached steady-state levels of nusinersen more quickly than those who received 3-and 6-mg doses. In addition, the clinically meaningful effect size for reduction in or stabilization of fatigue remains to be established. Longitudinal natural history studies that evaluate normal variability and trajectories in fatigue over time are needed.
This post hoc analysis has reported on levels of fatigue after nusinersen treatment and further extends and supports previous results demonstrating the clinically meaningful effects of nusinersen on motor function in children and adolescents with later-onset SMA (ie, those with or most likely to develop SMA type II or III). 20 
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